Public Employees Retirement System of Ohio Grows Stake in Eli Lilly and Company (NYSE:LLY)

Public Employees Retirement System of Ohio increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 19.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 479,489 shares of the company’s stock after purchasing an additional 79,176 shares during the quarter. Eli Lilly and Company makes up 1.3% of Public Employees Retirement System of Ohio’s portfolio, making the stock its 11th biggest holding. Public Employees Retirement System of Ohio owned approximately 0.05% of Eli Lilly and Company worth $370,166,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. FPC Investment Advisory Inc. boosted its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after buying an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $50,000. Fiduciary Advisors Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $58,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at approximately $66,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on LLY. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $714.84 on Friday. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market capitalization of $677.48 billion, a P/E ratio of 61.05, a P/E/G ratio of 1.40 and a beta of 0.48. The stock has a 50 day moving average price of $791.44 and a 200 day moving average price of $803.64.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the firm earned $2.58 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.84%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.